1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A

SSSE:688513
46.28
CNY
+1.23
(+2.73%)
1.38EPS
28.43P/E
7.76BMarket Cap
Oct 28Next Earn

Latest Stock Split

Jul 01, 2024

147:100

For every 100 shares held, investors received 147. The price per share adjusted from $50.29 to $34.21.

The split itself did not change the total investment value.

Use this split data in your app

Build with our data
Stock Splits APIChatGPT

Stock Split History

  1. Jul 01, 2024
    Before$50.29
    Split ratio147:100
    After$34.21
    Forward

About Chengdu Easton Biopharmaceuticals Co., Ltd. Class A stock splits

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A (SSE:688513) operates in the Pharmaceuticals: major industry.

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A company overview

When did Chengdu Easton Biopharmaceuticals Co., Ltd. Class A stock split?

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A's most recent stock split was on July 1, 2024. It was a 147-for-100 forward split, so shareholders received 147 shares for every 100 they held.

How many times has Chengdu Easton Biopharmaceuticals Co., Ltd. Class A stock split?

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A has split its stock once. This history records one forward split, on July 1, 2024.

What is a stock split?

A stock split divides each share into more shares and lowers the price per share by the same factor, so the total value of a holding does not change. In Chengdu Easton Biopharmaceuticals Co., Ltd. Class A's 147-for-100 split on July 1, 2024, every 100 shares became 147 shares.

Will Chengdu Easton Biopharmaceuticals Co., Ltd. Class A split its stock again?

Chengdu Easton Biopharmaceuticals Co., Ltd. Class A has not announced a new split in our records. Its most recent split was on July 1, 2024, 2 years ago. Companies announce splits in advance, and any new SSE:688513 split will appear on this page.